4[4]Chan AO,Broaddus RR,Houlihan PS,Issa JP,Hamilton SR,Rashid A.CpG island methylation in aberrant crypt foci of the colorectum.Am] Pathol 2002; 160:1823-1830
5[5]Belshaw NJ,Elliott GO,Williams EA,Bradbum DM,Mills SJ,Mathers JC,Johnson IT.Use of DNA from human stools to detect aberrant CpG island methylation of genes implicated in colorectal cancer.Cancer Epidemiol Biomarkers Prev 2004; 13:1495-1501
6[6]Leung WK,To KF,Man EP,Chan MW,Bai AH,HuiAJ,Chan FK,Lee JF,Sung JJ.Detection of epigenetic changes in fecal DNA as a molecular screening test for colorectal cancer:a feasibility study.Clin Chem 2004; 50:2179-2182
7[7]Muller HM,Oberwalder M,Fiegl H,Morandell M,Goebel G,Zitt M,Muhlthaler M,Ofner D,Margreiter R,Widschwendter M.Methylation changes in faecal DNA:a marker for colorectal cancer screening? Lancet 2004; 363:1283-1285
8[8]Petko Z,Ghiassi M,Shuber A,Gorham J,Smalley W,Washington MK,Schultenover S,Gautam S,Markowitz SD,Grady WM.Aberrantly methylated CDKN2A,MGMT,and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps.Clin Cancer Res 2005; 11:1203-1209
9[9]Lenhard K,Bommer GT,Asutay S,Schauer R,Brabletz T,Goke B,Lamerz R,Kolligs FT.Analysis of promoter methylation in stool:a novel method for the detection of colorectal cancer.Clin Gastroenterol Hepatol 2005; 3:142-149
10[10]Chen WD,Han ZJ,Skoletsky J,Olson J,Sah J,Myeroff L,Platzer P,Lu S,Dawson D,Willis J,Pretlow TP,Lutterbaugh J,Kasturi L,Willson JK,Rao JS,Shuber A,Markowitz SD.Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene.J Natl Cancer Inst 2005; 97:1124-1132
6Muzny DM, Bainbridge MN, Chang K, et al. Comprehensive too-lecular characterization of human colon and rectal cancer[ J]. Na- ture, 2012, 487(7407): 330-337.
7Tone LA, Bray F, Siegel RL, et al. Global cancer statistics [ Jl. CA Cancer J Clin, 2011, 61(2): 69-90.
8Courtney RJ, Paul CL, Carey ML, et al. A population-based cross- sectionaX study of colorectal cancer screening practices of first-de- gree relatives of colorectal cancer patients [ J 1. BMC Cancer, 2013, 13(1): 1-11.
9Dahan L, Norguet E, Etienne- Grimaldi MC, et al. Pharmacogenet- ic profiling and cetuximab outcome in patients with advanced color- ectal cancer[J]. BMC Cancer, 2011, 11(1) : 496.
10Kostova E, Slaninka-Miceska M, Labacevski N, et al. Expression of matrix metalloproteinases 2,7 and 9 in patients with colorectal cancer[ J~. Vojnosanit Pregl, 2014, 71 ( 1 ) : 52-59.
